Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. May 6, 2015; 4(2): 254-262
Published online May 6, 2015. doi: 10.5527/wjn.v4.i2.254
Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?
Adrian Husillos Alonso, Manuel Carbonero García, Carmen González Enguita
Adrian Husillos Alonso, Manuel Carbonero García, Carmen González Enguita, Servicio de Urología, Hospital Universitario Infanta Elena (HUIE), 28340 Valdemoro, Madrid, Spain
Author contributions: Husillos Alonso A designed, performed, analyzed data and wote the paper; Carbonero García M and González Enguita C contributed equally to the writing of the manuscript and designing the aim of the review.
Conflict-of-interest: The authors declared no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Adrian Husillos Alonso, MD, Servicio de Urología, Hospital Universitario Infanta Elena (HUIE), Avda. Reyes Católicos 21, 28340 Valdemoro, Madrid, Spain.
Telephone: +34-91-8948410 Fax: +34-91-8948544
Received: November 28, 2014
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: January 18, 2015
Accepted: February 4, 2015
Article in press: February 9, 2015
Published online: May 6, 2015
Core Tip

Core tip: We have made a search in Pubmed database looking for evidence to support adjuvant systemic therapy after metastasectomy in metastatic renal cell carcinoma. As far as we know, evidence is low and it’s based in case reports and small series of patients. Despite the limitations and high risk of bias, promising results and cases with long-term survival with this approach have been described. Two ongoing clinical trials may answer the question that concerns us.